Roles of miRNAs in Colorectal Cancer: Therapeutic Implications and Clinical Opportunities

Amir Mehrgou ¹ , Shima Ebadollahi ², Khaled Seidi ³, Mohammad Hosein Ayoubi-Joshaghani ^4,5, Amirhossein Ahmadieh Yazdi ⁶, Peyman Zare ^7,8, Mehdi Jaymand ⁹ * , Rana Jahanban-Esfahlan ^10,11 *

Cited by CrossRef: 2

1- Sharifi-Azad M, Fathi M, Cho W, Barzegari A, Dadashi H, Dadashpour M, Jahanban-Esfahlan R. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(1) [Crossref]

2- Niemira M, Bielska A, Chwialkowska K, Raczkowska J, Skwarska A, Erol A, Zeller A, Sokolowska G, Toczydlowski D, Sidorkiewicz I, Mariak Z, Reszec J, Lyson T, Moniuszko M, Kretowski A. Circulating serum miR-362-3p and miR-6721-5p as potential biomarkers for classification patients with adult-type diffuse glioma. Front Mol Biosci. 2024;11 [Crossref]

3- Baldasici O, Balacescu L, Cruceriu D, Roman A, Lisencu C, Fetica B, Visan S, Cismaru A, Jurj A, Barbu-Tudoran L, Pileczki V, Vlase L, Tudoran O, Balacescu O. Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients. IJMS. 2022;23(20):12625 [Crossref]